Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Eduardo Huarte, PhD, Michael Peel, PhD, Philip Dube, PhD, Lynn Stephens, Becky Stewart, Brian Long, Philip Czerniak, Julian Oliver, PhD, Paul Smith, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139805

Published: 2020

Journal Articles

Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis

Eduardo Huarte, PhD, Michael Peel, PhD, Katherine Verbist, PhD, Brittany Fay, Sabrin Albeituni, PhD, Kim E. Nichols, MD, Paul Smith, PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-139539

Published: 2020

Journal Articles

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Eduardo Huarte, PhD, Roddy S O'Connor, PhD, Melissa Parker, Taisheng Huang, Michael C. Milone, Paul Smith

Blood (2019) 134 (Supplement_1): 1934.

https://doi.org/10.1182/blood-2019-128288

Published: 2019

Journal Articles

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Eduardo Huarte, PhD, Melissa Parker, Ashish Juvekar, Julian Oliver, Wenqing Yao, Paul Smith

Blood (2019) 134 (Supplement_1): 5608.

https://doi.org/10.1182/blood-2019-126749

Published: 2019

Journal Articles

PILAR is a novel modulator of human T-cell expansion

Eduardo Huarte, Juan R. Cubillos-Ruiz, Yolanda C. Nesbeth, Uciane K. Scarlett, Diana G. Martinez, Xavier A. Engle, William F. Rigby, Patricia A. Pioli, Paul M. Guyre, Jose R. Conejo-Garcia

Blood (2008) 112 (4): 1259–1268.

https://doi.org/10.1182/blood-2007-12-130773

Published: 2008

Includes: Supplemental data

NARROW

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

PILAR is a novel modulator of human T-cell expansion

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis

Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

PILAR is a novel modulator of human T-cell expansion

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only